• LinkedIn

Before becoming CEO, Dr. Cherukuri served in multiple roles at Noble Life Sciences including Chief Operations Officer, Chief Scientific Officer, Vice President of Product Development and Operations, and Director of Scientific Affairs. In her previous roles at Noble, Dr. Cherukuri was instrumental in optimizing new preclinical animal models and streamlining operations to achieve operational efficiency. In addition, Dr. Cherukuri led the successful consolidation of Noble operations at the Spring Valley Laboratories site. Prior to joining Noble, Dr. Cherukuri held positions at the Cleveland Clinic Foundation, National Cancer Institute and University of Maryland where she led projects focused on understanding the basic biology and mechanistic actions in cancer cells. Dr. Cherukuri has expertise in diverse areas of Biology and has 12+ years of research experience in the areas of oncology and stem cell biology. Dr. Cherukuri completed her PhD in biology at Cleveland State University.

• LinkedIn

Mr. Cappeluti has more than 30 years of experience in finance and public accounting for private and public companies, with more than 20 of those years spent in the biotech industry working for BioReliance, Human Genome Sciences (HGS), and CoGenesys. As the second employee of HGS in 1992 at the start of the human gene sequencing effort, he held positions of increasing responsibility and served for many years as Vice President of Finance. He has managed both large and small internal financial operations and has participated directly in approximately $4 billion of corporate financing transactions including private and public financings; IPOs; mergers and acquisitions; and real estate transactions. He led one of the largest real estate transactions in Maryland history while at HGS when the company executed a sale lease back on its corporate headquarters and large scale GMP manufacturing facilities. Mr. Cappeluti was part of the team that spun out Cogenesys from HGS in 2006 and was the CFO until the company was sold to Teva Pharmaceuticals in 2008. As a customer of CRO services in previous biotechnology industry positions, Mr. Cappeluti developed a keen awareness of quality and service issues that inform his leadership at Noble. He also serves on the board of O-Traces, Inc., an early stage cancer diagnostics company, and is a consultant to other life science companies.

• LinkedIn

Dr. Horrigan is an accomplished molecular geneticist who is known for his contributions to the development of innovative approaches for using genomic profiles and biomarkers to enhance drug discovery and development. Prior to joining Noble, Dr. Horrigan was the Vice President of Research at Avalon Pharmaceuticals a wholly-owned subsidiary of Clinical Data, Inc. During his tenure at Avalon, he held several positions of increasing responsibility within the research organization while directing both internal and collaborative research programs. He also played a key leadership role in the development of the company’s unique genomic biomarker-driven R&D platform. Dr. Horrigan has a strong expertise in the cellular control mechanisms of cancer and the use of biomarkers for the discovery and development of therapeutics and has multiple publications and patents in this area. Prior to joining Avalon, Dr. Horrigan was Associate Professor in the Department of Pediatrics and Lombardi Cancer Center at Georgetown University Medical Center where he led a research group focused on cancer genomics and the application of biomarkers in cancer diagnostics. He has also held positions at the University of Illinois, College of Medicine and the University of Chicago School of Medicine.

• LinkedIn

Dr. Carter has been involved in the formation and early stage development of several biotechnology companies as a co-founder, consultant or member of the board of directors. He co-founded Avalon Pharmaceuticals, Inc. in January 1999 and served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During this time, Avalon developed a unique biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established drug discovery programs in colon, breast, pancreatic and hematological cancers; and established partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune. Prior to that, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he worked for several years and played a role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter has served on the boards of directors for multiple biotechnology industry organizations including the Maryland Health Care Product Development Corporation and the National BIO Industry Organization. He also served recently as a special advisor to the Maryland Governor’s Life Sciences Advisory Board and is on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he also holds an adjunct faculty appointment.

• LinkedIn

Dr. Parsley has over twenty years experience in microbiology, molecular biology and infectious disease research with an emphasis on pathogen-host interactions, viral replication/gene expression and pathogen resistance. He directs and manages research projects for development of antimicrobial agents for viruses, bacteria, and fungi for both internal research and contract research services. He also leads Noble’s Hepatitis Virus research programs. At Noble, Dr. Parsley develops, modifies, and optimizes molecular assays for use in the identification, detection, and quantification of infectious organisms and host gene expression.

• LinkedIn

Dr. Sanchez has 25+ years of laboratory animal and pre-clinical research experience. He has directed and managed FDA/EPA-compliant GLP studies and has served in the roles of study director, study administrator, and quality assurance. Dr. Sanchez has also served as Chair and Vice-Chair of the GLP University Subsection for the Society of Quality Assurance and is a former faculty member in the Department of Pathology, Medicine, at the University of Maryland School of Medicine.

• LinkedIn

Ms. Shaw has 20+ years of experience in the contract research industry with a broad perspective in research toxicology, immunology, and infectious diseases. She has extensive knowledge in preclinical studies in acute, subacute, and chronic toxicity in GLP environments.  She also is knowledgeable of regulatory documents including The Guide for the Care and Use of Laboratory Animals, The Animal Welfare Act, Public Health Service Policies, the AVMA Guidelines, and the US FDA’s GLPs. Prior to joining Noble, she was the Director of Preclinical Services at Spring Valley Laboratories, Inc.

• LinkedIn

Dr. Shipley has spent 20 years as a full-time Laboratory Animal Veterinarian conducting research and supporting studies in infectious disease/vaccine development, genetic disorders, transplant immunology, medical device development, pharmacology/drug development, and cancer research. He is a Diplomate of the American College of Laboratory Animal Medicine and has an emphasis on large animal surgical models and animal program management.

• LinkedIn

Bidi Bolarin, M.P.A has 22 years of experience in telecommunications, electricity regulations, and human resources. She graduated with JD from the University of Ilorin, Nigeria, and she has a Masters in Public Administration, with a Human Management concentration, from Rutgers University Camden, NJ. Prior to Noble, she was a Human Resources Manager at Clover Contracting LLC.

• LinkedIn

Dr. Tatarov has 15+ years of experience in Laboratory Animal Medicine. He provides veterinary medical care and utilizes a variety of laboratory animals in medical research in compliance with Federal regulations and Good Laboratory Practice. Prior to Noble Life Sciences worked as a clinical research veterinarian at the University of Maryland School of Medicine.